These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 29511897)
1. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Gonzalez-Duarte A Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897 [TBL] [Abstract][Full Text] [Related]
2. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Conceição I Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774 [TBL] [Abstract][Full Text] [Related]
3. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy. Gendre T; Planté-Bordeneuve V Clin Auton Res; 2019 Sep; 29(Suppl 1):25-31. PubMed ID: 31506870 [TBL] [Abstract][Full Text] [Related]
4. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713 [TBL] [Abstract][Full Text] [Related]
5. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023 [TBL] [Abstract][Full Text] [Related]
6. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Cruz MW Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119 [TBL] [Abstract][Full Text] [Related]
7. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300 [TBL] [Abstract][Full Text] [Related]
8. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406 [TBL] [Abstract][Full Text] [Related]
9. Burden of hereditary transthyretin amyloidosis on quality of life. Yarlas A; Gertz MA; Dasgupta NR; Obici L; Pollock M; Ackermann EJ; Lovley A; Kessler AS; Patel PA; White MK; Guthrie SD Muscle Nerve; 2019 Aug; 60(2):169-175. PubMed ID: 31093980 [TBL] [Abstract][Full Text] [Related]
10. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. Gonzalez-Duarte A; Valdés-Ferrer SI; Cantú-Brito C Clin Auton Res; 2019 Sep; 29(Suppl 1):1-9. PubMed ID: 31473866 [TBL] [Abstract][Full Text] [Related]
11. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis. Nie T; Heo YA; Shirley M Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865 [TBL] [Abstract][Full Text] [Related]
13. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. Conceição I; Miranda B; Castro J; de Carvalho M Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456 [TBL] [Abstract][Full Text] [Related]
14. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166 [TBL] [Abstract][Full Text] [Related]
15. Neuropathy Associated with Systemic Amyloidosis. Kaku M; Berk JL Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841 [TBL] [Abstract][Full Text] [Related]
16. Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches. Serrano D; Atzinger CB; Botteman MF Neurol Ther; 2018 Jun; 7(1):141-154. PubMed ID: 29611130 [TBL] [Abstract][Full Text] [Related]
17. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS). González-Duarte A; Barroso F; Mundayat R; Shapiro B Auton Neurosci; 2019 Dec; 222():102590. PubMed ID: 31726319 [TBL] [Abstract][Full Text] [Related]
18. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156 [TBL] [Abstract][Full Text] [Related]